1887
Volume 2026, Issue 1
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Septic shock is a severe medical emergency with high mortality, characterized by circulatory failure and dysfunction of vital organs. Despite initial fluid resuscitation, only 50% of patients respond, requiring the use of vasopressors. Methylene blue (MB) has emerged as a treatment for refractory vasoplegia, restoring vascular tone and reducing inflammatory cytokines; however, its use in the early stages of shock remains under-researched. The objective of this study is to explore the existing literature on the use of MB in the early stages of septic shock to evaluate its effectiveness and safety.

An exploratory systematic review was conducted in accordance with PRISMA-ScR guidelines. Analytical or experimental human studies, retrospective or prospective, published up to February 25, 2025, were included. The databases searched included PubMed, Scopus, the International Clinical Trials Registry Platform (ClinicalTrials), OXFORD academy, and EBSCO. Terms such as “Early shock” and “Methylene Blue” were primarily searched.

A total of six publications published between 2001 and 2025 evaluated MB in septic shock. Most studies showed that early MB use improved hemodynamic parameters, reduced vasopressor duration, and showed possible immunomodulatory effects. No major safety concerns were reported across studies.

MB may be considered as a complementary strategy in the management of septic shock, particularly in its early stages. Its positive impact on hemodynamics, its safety in controlled doses, and its potential role as an immunomodulator make it a promising therapeutic option.

© 2026 Díaz, Puentes, Rubiano, Burgos, Caycedo, Goyes, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2026.14
2026-02-02
2026-02-04

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2026/1/jemtac.2026.14.html?itemId=/content/journals/10.5339/jemtac.2026.14&mimeType=html&fmt=ahah

References

  1. Baumer-Mouradian SH, Drendel AL. Shock. Nelson pediatric symptom-based diagnosis: Common diseases and their mimics [Internet]. 2023 Jul 24 [cited 2025 Apr 16]. 177–89.e1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531492/
     [Google Scholar]
  2. La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S, et al. The global burden of sepsis and septic shock. Epidemiologia (Basel). 2024 Jul 25; 5:(3):456–78. https://doi.org/10.3390/epidemiologia5030032
    [Google Scholar]
  3. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019-results from a systematic review and meta-analysis. Crit Care. 2020 May 19; 24:(1):239. https://doi.org/10.1186/s13054-020-02950-2
    [Google Scholar]
  4. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the global burden of disease study. Lancet. 2020 Jan 18; 395:(10219):200–11. https://doi.org/10.1016/S0140-6736(19)32989-7
    [Google Scholar]
  5. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016 Feb 23; 315:(8):801–10. https://doi.org/10.1001/jama.2016.0287
    [Google Scholar]
  6. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov; 47:(11):1181–247. https://doi.org/10.1007/s00134-021-06506-y
    [Google Scholar]
  7. Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016 Sep 27; 316:(12):1298–309. https://doi.org/10.1001/jama.2016.12310
    [Google Scholar]
  8. Kofler O, Simbeck M, Tomasi R, Hinske LC, Klotz LV, Uhle F, et al. Early use of methylene blue in vasoplegic syndrome: A 10-year propensity score-matched cohort study. J Clin Med. 2022 Feb 20; 11:(4):1121. https://doi.org/10.3390/jcm11041121
    [Google Scholar]
  9. Rajbanshi LK, Bajracharya A, Arjyal B, Devkota D. Can use of intravenous methylene blue improve the hemodynamics and outcome of the patients with refractory septic shock? An observational study. Indian J Crit Care Med. 2023 Sep; 27:(9):669–74. https://doi.org/10.5005/jp-journals-10071-24535
    [Google Scholar]
  10. Naoum EE, Dalia AA, Roberts RJ, Devine LT, Ortoleva J. Methylene blue for vasodilatory shock in the intensive care unit: A retrospective, observational study. BMC Anesthesiol. 2022 Jun 27; 22:(1):199. https://doi.org/10.1186/s12871-022-01739-w
    [Google Scholar]
  11. Ramamoorthy S, Patel S, Bradburn E, Kadry Z, Uemura T, Janicki PK, et al. Use of methylene blue for treatment of severe sepsis in an immunosuppressed patient after liver transplantation. Case Rep Transplant. 2013 Jan 1; 2013:(1):203791. https://doi.org/10.1155/2013/203791
    [Google Scholar]
  12. Elbayomi M, Dewald O, Pathare P, Kondruweit M, Tandler R, Weyand M, et al. The mystery of methylene blue and its role in managing post-cardiac surgery vasoplegic shock. Ann Med. 2025 Dec; 57:(1):2460770. https://doi.org/10.1080/07853890.2025.2460770
    [Google Scholar]
  13. Luis-Silva F, Menegueti MG, Sato L, Peres LM, Dos Reis Sepeda C, Petroski-Moraes BC, et al. Effect of methylene blue on hemodynamic response in the early phase of septic shock: A case series. Medicine (Baltimore). 2023 Jan 27; 102:(4):E32743. https://doi.org/10.1097/MD.0000000000032743
    [Google Scholar]
  14. Ibarra-Estrada M, Kattan E, Aguilera-González P, Sandoval-Plascencia L, Rico-Jauregui U, Gómez-Partida CA, et al. Early adjunctive methylene blue in patients with septic shock: A randomized controlled trial. Crit Care. 2023 Mar 13; 27:(1):110. https://doi.org/10.1186/s13054-023-04397-7
    [Google Scholar]
  15. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018 Oct 2; 169:(7):467–73. https://doi.org/10.7326/M18-0850
    [Google Scholar]
  16. Arksey H, O’Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol Theory Practice. 2005; 8:(1):19–32. https://doi.org/10.1080/1364557032000119616
    [Google Scholar]
  17. Levac D, Colquhoun H, O’Brien KK. Scoping studies: Advancing the methodology. Implement Sci. 2010 Dep 20; 5:(1):69. https://doi.org/10.1186/1748-5908-5-69
    [Google Scholar]
  18. Abd-Alhameed AE, Hamed AMS, Omran AS. Methylene blue: Role in early management of septic shock patients? Ain-Shams J Anaesthesiol. 2014 Jan; 7:(3):327. https://doi.org/10.4103/1687-7934.139558
    [Google Scholar]
  19. Kuri HR, Sharma A, Meshram T, Kothari N, Goyal S, Paliwal B, et al. Effects of early use of methylene blue and vasopressin on noradrenaline dose in septic shock: A randomized controlled trial. Indian J Crit Care Med. 2025 Feb; 29:(2):108–12. https://doi.org/10.5005/jp-journals-10071-24905
    [Google Scholar]
  20. Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjørnsson B, et al. Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study. Crit Care Med. 2001 Oct; 29:(10):1860–7. https://doi.org/10.1097/00003246-200110000-00002
    [Google Scholar]
  21. Shaker EH, Soliman AM, Bedewy AAE, Elrawas MM. Comparative study between high and low dose methylene blue infusion in septic cancer patients: A randomized, blinded, controlled study. BMC Anesthesiol. 2025 Jan 8; 25:(1):15. https://doi.org/10.1186/s12871-024-02792-3
    [Google Scholar]
  22. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996 Jul; 22:(7):707–10. https://doi.org/10.1007/BF01709751
    [Google Scholar]
  23. Singh J, Lee Y, Kellum JA. A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach. Crit Care. 2022 Aug 12; 26:(1):246. https://doi.org/10.1186/s13054-022-04075-0
    [Google Scholar]
  24. Bakker J, Kattan E, Annane D, Castro R, Cecconi M, De Backer D, et al. Current practice and evolving concepts in septic shock resuscitation. Intensive Care Med. 2022 Feb; 48:(2):148–63. https://doi.org/10.1007/s00134-021-06595-9 .
     [Google Scholar]
  25. Weingartner R, Oliveira E, Oliveira ES, Sant’Anna UL, Oliveira RP, Azambuja LA, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res. 1999 Dec; 32:(12):1505–13. https://doi.org/10.1590/s0100-879x1999001200009 .
     [Google Scholar]
  26. Zhao CC, Zhai YJ, Hu ZJ, Huo Y, Li ZQ, Zhu GJ. Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis. Front Med (Lausanne). 2022 Sep 26; 9::950596. https://doi.org/10.3389/fmed.2022.950596
    [Google Scholar]
  27. Ballarin RS, Lazzarin T, Zornoff L, Azevedo PS, Pereira FWL, Tanni SE, et al. Methylene blue in sepsis and septic shock: A systematic review and meta-analysis. Front Med (Lausanne). 2024 Apr 18; 11:1366062. https://doi.org/10.3389/fmed.2024.1366062
    [Google Scholar]
  28. Arias-Ortiz J, Vincent JL. Administration of methylene blue in septic shock: pros and cons. Crit Care. 2024Feb 16; 28:(1):46. https://doi.org/10.1186/s13054-024-04839-w
    [Google Scholar]
  29. Juffermans NP, Vervloet MG, Daemen-Gubbels CRG, Binnekade JM, de Jong M, Groeneveld ABJ. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide. 2010 May 15; 22:(4):275–80. https://doi.org/10.1016/j.niox.2010.01.006
    [Google Scholar]
  30. Venkatesh B, Khanna AK, Cohen J. Less is more: Catecholamine-sparing strategies in septic shock. Intensive Care Med. 2019 Dec; 45:(12):1810–2. https://doi.org/10.1007/s00134-019-05770-3
    [Google Scholar]
  31. Sahoo DK, Wong D, Patani A, Paital B, Yadav VK, Patel A, et al. Exploring the role of antioxidants in sepsis-associated oxidative stress: a comprehensive review. Front Cell Infect Microbiol. 2024 Mar 6; 14:1348713. https://doi.org/10.3389/fcimb.2024.1348713
    [Google Scholar]
  32. Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002 Dec; 30:(6):755–62. https://doi.org/10.1177/0310057X0203000606
    [Google Scholar]
/content/journals/10.5339/jemtac.2026.14
Loading
Use of methylene blue in early septic shock: A scoping review
Journal of Emergency Medicine, Trauma and Acute Care 2026, 14 (2026); https://doi.org/10.5339/jemtac.2026.14
/content/journals/10.5339/jemtac.2026.14
/content/journals/10.5339/jemtac.2026.14
Loading

Data & Media loading...

  • Article Type: Review Article
Keyword(s): critical care, methylene blue, mortality, septic, shock and vasoconstrictor agents

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error